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Background: This study investigated the antinociceptive effects of a constant rate infusion (CRI) of lidocaine during
xylazine and ketamine anesthesia in horses and aimed to correlate these effects with cardiorespiratory variables,
bispectral index (BIS) and plasma lidocaine concentrations. Six adult crossbred mares weighing 320–400 kg were
anesthetized on three different occasions. Sedation was performed with xylazine (0.75 mg/kg IV) and anesthetic
induction with guaifenesin (75 mg/kg IV) and ketamine (2 mg/kg IV). Anesthesia was maintained with 37.5 μg/kg/
min of xylazine and 87.5 μg/kg/min of ketamine both administered intravenously for 75 min. The three treatments
consisted of: lidocaine (loading dose: 5 mg/kg, CRI: 100 μg/kg/min; THL); lidocaine (loading dose: 2.5 mg/kg; CRI:
50 μg/kg/min: TLL); and saline (TS); all given 15 min after induction and maintained for 1 h. Antinociception was
measured by response to electrical stimulation and bispectral index (BIS) was recorded during anesthesia.
Parametric and non-parametric data were compared using ANOVA followed by Student-Newman-Keuls and
Friedman tests, respectively.
Results: Plasma lidocaine concentrations peaked at the end of lidocaine loading dose and was greater in THL
(9.61 ± 2.75 μg/mL) vs TLL (4.50 ± 3.34 μg/mL). Electrical noxious stimulation caused purposeful movement in all
horses from TS, but no response in THL. The BIS was decreased in THL only and was less when compared to the
other treatments throughout anesthesia. Blood pressure, PaO2 and PaCO2 increased and heart rate (HR),
respiratory rate (RR), pH, total plasma protein and temperature decreased during anesthesia in all treatments.
PaCO2 and HR were greater and RR and pH less in THL compared to TLL and TS at 30 min during anesthesia. All
recoveries were considered excellent. Time to standing was longer after THL (60 ± 20 min) than following TLL and
TS (32 ± 17 and 30 ± 15 min, respectively).
Conclusions: At the highest dose administered (THL) lidocaine CRI during xylazine/ketamine anesthesia decreased
BIS and motor response to noxious stimulation, and prolonged recovery time without significant added
cardiorespiratory depression.
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The continuous intravenous (IV) infusion (CRI) of the
combination of α2-adrenoceptor agonists and ketamine
has been extensively studied in horses [1-7]. These com-
binations may provide less cardiorespiratory depression
with no endocrine stress response when compared to
inhalation anesthesia [2,4,5,8]. Also, the combination of
xylazine and ketamine produces a mild increase in ar-
terial blood pressure and a reduction of the respiratory
rate and respiratory acidosis [3,9].
Lidocaine has a number of beneficial effects when
administered IV or intramuscularly (IM). It produces
systemic analgesia [10-13] and reduces the dose of
thiopentone necessary to produce hypnosis in humans
[14], dogs [15] and goats [16]. Also, lidocaine constant
rate infusion (CRI) reduced the MAC of halothane in
both, dogs and horses, from 10% to 45% and 30% to
70%, respectively [10,17]. It reduced MAC of isoflurane
by 25% in horses [18], 18.3% in goats [19], and MAC of
sevoflurane by 26.7% in horses [20].
The BIS is a number produced by decomposition of
the electroencephalogram (EEG) recording and it is
quantified by the level of the synchronization signal
with the amplitude and frequency (bispectral analysis).
Therefore, it is a simplified description of the complex
EEG patterns in only one number [21]. In humans a
BIS score of 100 means a completely conscious (alert)
patient, a score of 70 means a discreet consciousness,
and numerical values of 60, 40, and 0 correspond to
moderate, deep and very deep hypnosis [21,22]. The
BIS is used for measuring the degree of hypnosis during
anesthesia [21,23]. Systemic lidocaine levels decrease BIS
and are able to suppress it to 0 [24].
Based on the hypothesis that a CRI of lidocaine
would potentiate antinociception and decrease BIS
without compromising cardiorespiratory variables, the
objective of this study was to investigate the anesthetic
effects of a CRI of lidocaine during xylazine and keta-
mine anesthesia in horses and to correlate these effects
with cardiorespiratory variables, BIS and plasma lido-
caine concentrations.
Methods
This study was approved by the Institutional Research
Animal Care Committee. Six clinically healthy cross-
bred Mangalarga Paulista mares, from 5 to 12 (8 ± 3)
years of age and weighing between 320 and 400 kg
(356.5 ± 31) were used. Animals were provided by the
University farm. They were administered gastrointestinal
anti-parasitic medication (Eqvalan pasta–Merk, Sharp &
Dohme Farm. e Vet. Ltda.) two weeks before the study
and housed under field conditions eating Coast-cross hay
and commercial concentrated feed. Each animal was anes-
thetized on three different occasions using a randomizedcrossover design, with a washout period of two weeks
between treatments. The investigator responsible for
scoring muscle relaxation and recovery was blinded to
the treatments.
Xylazine/ketamine infusion doses used in this study
came from a pilot study involving ten other horses to es-
tablish the minimal infusion rate capable to maintain ani-
mals immobilized [25]. Immediately prior to study, horses
were housed in stalls and food was withheld for 12 hours
prior to anesthesia; water was always available. On the
morning of the study, animals were weighed and placed in
standing stocks for jugular placement of a 14G catheter
(Insyte, Becton Dickinson Ind. Cir. Ltda.) using standard
aseptic technique. Animals were sedated with 0.75 mg/kg
of xylazine IV (Sedazine 10%, Fort Dodge Saude Animal
Ltda.), and 5 minutes later anesthesia was induced with
75 mg/kg of 10% guaifenesin IV (Eter gliceril guaiacol,
Henrifarma Prod. Quim. e Farm. Ltda) and 2 mg/kg of
ketamine IV (Vetaset 10%, Fort Dodge Saude Animal
Ltda). Immediately after anesthetic induction, the ani-
mals received a constant infusion of 37.5 μg/kg/min of
xylazine and 87.5 μg/kg/min of ketamine. Animals were
orotracheally intubated, placed in left lateral recum-
bency, and connected to a large animal circle anesthetic
machine (VML Anesthesia Machine, Matrix Medical
Inc.) without a vaporizer in the circuit. The circle system
was previously washed out with a flow of 5 L/min of O2
over five minutes to ensure an inspired O2 concentration
(Monitor Cardiocap 5, Datex Ohmeda) close to 100%.
After the horse’s endotracheal tube was connected to the
anesthetic circuit, the O2 flow was adjusted to 10 mL/kg/
minute and a gas analyser (Cardiocap 5, Datex Ohmeda)
was used to confirm the absence of any volatile anesthetic
in the circuit. A 20G catheter was placed in the transverse
facial artery for arterial blood pressure measurement and
arterial blood sampling.
Fifteen minutes after induction one of three treat-
ments was randomly administered as follows:
Treatment 1 (THL): 5 mg/kg bolus of lidocaine
(Xylocaina 2%, Astra Química e Farmacêutica Ltda.)
was administered IV over 5 minutes, followed by a CRI
of 100 μg/kg/min.
Treatment 2 (TLL): 2.5 mg/kg bolus of lidocaine
(Xylocaina 2%, Astra Química e Farmacêutica Ltda.)
was administered IV over 5 minutes, followed by a CRI
of 50 μg/kg/min. Lidocaine was diluted to 1% with
normal saline (0.9% NaCl) to ensure the same volume
of injection as THL.
Treatment 3 (TS): Normal saline (0.9% NaCl) was
administered at the same volume as the other two
treatments following the same administration
procedure. Over the course of study each horse
received all three treatments.
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staltic pump (LF 2001, Lifemed Pesquisas Médicas Ind.
Com. Ltda.). All infusions were stopped 75 minutes
after induction and the animals were positioned on the
recovery room floor, in the same lateral recumbency as
during anesthetic period. They were then extubated and
continuously observed until they stood without assistance.
Measurements
Heart rate (HR) was monitored via continuous ECG using
a base-apex lead placement configuration. Arterial blood
pressure (ABP) was measured by a transducer calibrated
against a mercury column before the beginning of each
experiment connected to the transverse facial artery
catheter (Cardiocap 5, Datex Ohmeda). Respiratory rate
was monitored by a tubing adapted to the “Y” of the
circle circuit during anesthesia (Cardiocap 5, Datex
Ohmeda). The analyzer was calibrated before each ex-
periment with a standardized calibration gas mixture
supplied by the manufacturer (Quick Cal Calibration
Gas; Datex-Ëngstrom, Finland). The altitude of the loca-
tion of the study was 870 m.
Arterial blood gases, plasma glucose, and plasma lac-
tate were measured from heparinized blood samples
collected from the transverse facial artery (RapidLAB
865, Chiron Diagnostics). All samples were placed on
ice and measured within two hours after collection.
Total plasma protein (TPP) was measured using refractom-
etry (Refractometer ATAGO–SPR T2). Rectal temperature
(T°C) was monitored by using a digital clinical thermom-
eter (Becton Dickinson Ind. Cir. Ltda.).
The BIS values were measured using cutaneous elec-
trodes placed on the frontal and temporal cephalic re-
gion and connected to a BIS monitor (A-2000 Bispectral
Index Monitor, Aspect Medical Systems, Inc.).
Muscle relaxation was evaluated using a score from 0
to 3 according to the following scale: 0 =muscle relax-
ation of trunk and limbs; 1 = muscle tremors in some
regions of the trunk and limbs; 2 = muscle tremors in
most parts of the trunk and limbs; 3 = rigidity of most
parts of the trunk and limbs.
All measurements were performed immediately before
xylazine administration (T0), and at 5 (T5), 15 (T15), 20
(T20), 30 (T30), 45 (T45), 60 (T60), and 75 (T75) minutes
after induction of anesthesia, except for ABP and muscle
relaxation which were not measured at T0. Blood gases,
TPP, rectal temperature, and biochemical parameters
were not measured at T20. BIS was not measured at T0
and was further evaluated five minutes after the end of
anesthesia (T80).
To evaluate antinociception, a standardized electrical
stimulus (GRASS S-48 nerve stimulator) of 50 V, 5 Hz,
10 ms was applied via electrodes connected to 0.80 × 30
(21G× 1 ¼) metallic needles introduced in the subgengivalarea two cm parallel to the molars. The stimulus was
applied until there was associated purposeful movement
of head, neck, or limbs or for a full 60 seconds if no pur-
poseful movement occurred. The stimulus was applied at
T15, T30, T60, and T75 after all measurements and blood
samples had been collected for that time point.
Lidocaine plasma concentration was measured by high
performance liquid chromatography (HPLC Sistem LC-
10VP, Suimadzu Corporation) according to the method
described by Doherty & Frazier (1998). Blood samples
for lidocaine analysis were collected from the transverse
facial artery at T0, T20, T30, T45, T60, T75 and T80 and
placed in heparinised tubes. The plasma was harvested
and stored at −80°C until analysis. At analysis time plasma
samples were defrosted and homogenized. A plasma sam-
ple of 1 mL was mixed to 50 μl of trimetoprim (internal
standard, 25 μg/mL). Sodium hydroxide (200 μl, 1 M) and
methylene chloride (4 mL) were added to each sample,
vortexed for 15 minutes, and centrifuged for 2000 rpm for
15 minutes. The sediment was reconstituted with 1 mL of
mobile phase (isocratic mixture of 0.03 mol/L potassium
dihydrogen phosphate:acetonitrile - 87:13 v/v) and ali-
quots of 180 μl were injected in the chromatograph
(LC-10VP, Suimadzu Corporation), using a 2 mL/min
flow and ultraviolet absorbance at 205 nm. Recovery
ranged from 82% to 100%. Intra- and inter-assay variability
was 2.7% and 4.5% respectively. The limit of detection was
0.031 μg/mL.
Recovery from anesthesia was observed and classified
according a previously cited [8] simple descriptive scale
where 5 = excellent–no struggling, standing at the first
attempt, 4 = good–slight ataxia, but good stability, 3 =
tolerable–some ataxia when standing, two or three unsuc-
cessful attempts to stand, 2 = bad–excitement, paddling
when in recumbency, marked ataxia with possible fall, and
1 = very bad–excitement during recumbency, many un-
successful attempts to stand, ataxia and falls after stand-
ing, risk of trauma. Time from the end of anesthesia to
standing was recorded.
Statistical method
Statistical analysis was performed with a commercial
software program (GraphPad InStat, GraphPad Software
Inc.). The parametric data were compared using analysis
of variance for repeated measures followed by Student-
Newman-Keuls Test. The non-parametric data were
compared using analysis of variance followed by Friedman
test. The level of significance was set at 0.05. Continuous
data are presented as mean ± standard deviation (SD).
Results
Maximum plasma lidocaine concentrations were achieved
at T20 in THL and TLL and were 9.61 ± 2.75 and 4.50 ±










Figure 1 Mean (SD) plasma lidocaine concentration in mares undergoing intravenous anesthesia with xylazine, guaifenesin and ketamine
combined with a high (THL) or low lidocaine (TLL) dose infusion. a, b - statistical difference between treatments at a given time point.
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at 20 and 30 minutes of constant intravenous infusion.
The number of moves versus no moves in response to
noxious stimulation for the three groups of horses is
given in Table 1. In the absence of lidocaine, 20 out of
24 noxious stimulations caused purposeful movement
(TS). Conversely, there was no response to stimulation
during the administration of high dose lidocaine (THL).
There was no difference in muscle relaxation over time
or among treatments. The average scores ranged be-
tween 0 and 1.2 ± 0.8. Spontaneous muscular movementTable 1 Response to noxious stimulation (move/no move) an
undergoing intravenous anesthesia with xylazine, guaifenesin
(THL), low lidocaine dose (TLL) or saline infusion (TS) (n = 6)
Parameter Treat1
T5 T15 T2
Response to noxious stimulation THL 6/0
TLL 4/2
TS 4/2
BIS THL 97 ± 1 96 ± 4 63 ±
TLL 97 ± 1 96 ± 2 79 ±
TS 96 ± 3 92 ± 9 94 ±
1- Treat = Treatment; * - statistical difference from the baseline value (row) (P < 0.05
time point (column) (P < 0.05). For all means n = 6; T5 and T15–5 and 15 minutes af
respectively (and maintenance with xylazine and ketamine); T20, T30, T60, T75 and
dose (TLL) or saline infusion (TS) respectively.(sometimes seizure-like) was observed in the limbs, head,
and neck of all THL and in two of TLL horses. This was
observed at 3.0 ± 1.1 minutes after the lidocaine loading
bolus and starting the lidocaine infusion, and continued
for 3.2 ± 1.3 minutes thereafter.
There was a significant reduction in the BIS from T20 to
T75 in THL horses (Table 1). There were no significant
changes in BIS in TLL and TS horses during anesthesia.
Bispectral index values were significantly lower in THL
horses compared to the other treatments at all time points
from T30 to and including T75. Within 5 minutes of thed mean (±SD) bispectral index (BIS) values in mares
and ketamine combined with a high lidocaine dose
Time (minutes)




12*a 43 ± 11*a 45 ± 12*a 56 ± 19*a 63 ± 16*a 87 ± 15
26ab 75 ± 23b 84 ± 21b 87 ± 15b 91 ± 12b 97 ± 2
4b 95 ± 3b 98 ± 0b 97 ± 1b 98 ± 1b 98 ± 1
); different superscript letters indicate difference between treatments at each
ter induction of anesthesia with xylazine, guaifenesin and ketamine
T80–5, 15, 45, 60 and 65 minutes after high lidocaine dose (THL), low lidocaine
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was no longer significantly different from pre-lidocaine
values for this treatment, or for TLL and TS horses.
A decrease in heart rate followed anesthetic pre-
medication and induction with all three treatments, and
heart rate remained less than pre-drug values for TLL
and TS during the 75 minutes of anesthetic mainten-
ance (Table 2). On the other hand, heart rate was not
significantly different from pre-drug values in THL
horses within 5 minutes of the start of lidocaine admin-
istration (T20). There were no cardiac dysrhythmias
noted in any treatment. Arterial blood pressure was first
measured shortly following anesthetic induction andTable 2 Mean (±SD) heart rate (HR), systolic, medium and dia
PaCO2, respiratory rate (RR), pH and base excess (BE) in mare
guaifenesin and ketamine, combined with a high dose of lid
infusion (TS) (n = 6)
Parameter Treat1
T0 T5 T15
HR (bpm) THL 41 ± 5 35 ± 3* 33 ± 3*
TLL 39 ± 5 35 ± 3* 34 ± 3*
TS 42 ± 4 35 ± 4* 32 ± 2*
SAP (mmHg) THL - 138 ± 23 154 ± 23*
TLL - 141 ± 26 160 ± 28*
TS - 142 ± 24 168 ± 40*
MAP (mmHg) THL - 109 ± 17 120 ± 22*
TLL - 113 ± 19 126 ± 22*
TS - 109 ± 19 132 ± 32*
DAP (mmHg) THL - 92 ± 15 101 ± 21
TLL - 96 ± 14 106 ± 18*
TS - 92 ± 17 113 ± 27*
PaO2 (mmHg) THL 99 ± 8 266 ± 69
* 294 ± 74*
TLL 92 ± 3 315 ± 58* 319 ± 71*
TS 93 ± 4 256 ± 67* 287 ± 62*
PaCO2 (mmHg) THL 41 ± 5 55 ± 6
* 51 ± 5*
TLL 44 ± 3 52 ± 3* 53 ± 5*
TS 43 ± 3 52 ± 5* 53 ± 5*
RR (mpm) THL 20 ± 7 8 ± 3* 10 ± 3*
TLL 21 ± 4 8 ± 2* 10 ± 3*
TS 24 ± 7 9 ± 2* 8 ± 2*
pH THL 7.40 ± 0.03 7.34 ± 0.03* 7.36 ± 0.02*
TLL 7.42 ± 0.01 7.36 ± 0.01* 7.36 ± 0.03*
TS 7.42 ± 0.03 7.35 ± 0.03* 7.36 ± 0.03*
BE (mmol/L) THL 1.5 ± 1.7 2.3 ± 1.8 2.3 ± 2.3
TLL 3.0 ± 1.5 2.0 ± 1.0 2.9 ± 0.9
TS 2.7 ± 1.8 2.0 ± 1.4 3.2 ± 1.0
1- Treat = Treatment; * - statistical difference from the time 0 or baseline value (row
at each time point (column) (P < 0.05). For all means n = 6; T5 and T15–5 and 15 mi
respectively (and maintenance with xylazine and ketamine); T20, T30, T60, T75 and
dose (TLL) or saline infusion (TS) respectively.constant xylazine and ketamine rate infusion. The first
systolic, diastolic and mean arterial blood pressure
values were similar for each of the three treatments, and
they were the lowest of all subsequently determined
values within each treatment (Table 2).
Arterial blood gas and acid base values are given in
Table 2. An increase in PaO2 was associated with breath-
ing an oxygen enriched gas mixture during general
anesthesia. The PaCO2 also increased following induction
of anesthesia and remained elevated over the course of
anesthesia for all treatments. The values of PaCO2 and pH
for TLL and TS horses were similar and consistent over
the course of anesthesia, while these variables duringstolic arterial pressures (SAP, MAP and DAP), PaO2,
s undergoing intravenous anesthesia with xylazine,
ocaine (THL), low dose of lidocaine (TLL) or saline
Time (minutes)
T20 T30 T45 T60 T75
39 ± 8 37 ± 4a 36 ± 5 36 ± 5 37 ± 5
34 ± 2* 34 ± 3*b 34 ± 3* 35 ± 3* 35 ± 3*
33 ± 2* 32 ± 3*b 34 ± 4* 34 ± 4* 33 ± 4*
155 ± 17* 158 ± 18* 176 ± 21* 179 ± 20* 175 ± 11*a
163 ± 29* 168 ± 28* 177 ± 30* 173 ± 22* 175 ± 19*a
181 ± 42* 191 ± 43* 190 ± 34* 191 ± 26* 196 ± 24*b
123 ± 15* 125 ± 14* 139 ± 12* 146 ± 13* 146 ± 13*
129 ± 24* 132 ± 22* 139 ± 21* 140 ± 17* 144 ± 16*
142 ± 32* 147 ± 32* 143 ± 21* 146 ± 16* 147 ± 14*
105 ± 14* 108 ± 11* 118 ± 10* 124 ± 12* 128 ± 17*
110 ± 20* 113 ± 19* 117 ± 17* 120 ± 16* 124 ± 19*
120 ± 27* 123 ± 27* 119 ± 17* 121 ± 14* 121 ± 12*
- 262 ± 81* 262 ± 95* 261 ± 115* 251 ± 102*
- 305 ± 63* 305 ± 67* 291 ± 74* 290 ± 74*
- 269 ± 61* 277 ± 70* 284 ± 70* 283 ± 75*
- 59 ± 5*a 55 ± 5* 57. ± 5*a 56 ± 5*
- 53 ± 4*b 52 ± 4* 53 ± 3*b 54 ± 3*
- 53 ± 6*b 52 ± 6* 53 ± 5*b 53 ± 6*
11 ± 5* 8 ± 2*a 9 ± 2* 10 ± 3* 10 ± 3*a
9 ± 1* 10 ± 3*b 11 ± 2* 11 ± 2* 13 ± 4*ab
10 ± 2* 11 ± 3*b 14 ± 9* 17 ± 9* 16 ± 6*b
- 7.32 ± 0.02*a 7.35 ± 0.02* 7.36 ± 0.02* 7.36 ± 0.03*
- 7.35 ± 0.03*b 7.37 ± 0.03* 7.38 ± 0.02* 7.37 ± 0.02*
- 7.37 ± 0.04*b 7.38 ± 0.05* 7.38 ± 0.04* 7.39 ± 0.04*
- 2.3 ± 2.4 3.6 ± 3.1 4.9 ± 2.1* 4.6 ± 1.9*
- 2.4 ± 1.3 3.0 ± 0.9 4.4 ± 0.4* 4.8 ± 1.1*
- 3.8 ± 1.1* 4.0 ± 1.5* 4.7 ± 1.2* 5.2 ± 0.7*
) (P < 0.05); different superscript letters indicate difference between treatments
nutes after induction of anesthesia with xylazine, guaifenesin and ketamine
T80–5, 15, 45 and 60 minutes after high lidocaine dose (THL), low lidocaine
Nóbrega Neto et al. BMC Veterinary Research 2013, 9:199 Page 6 of 9
http://www.biomedcentral.com/1746-6148/9/199anesthesia for THL horses were slightly, but generally not
statistically significantly, greater (PaCO2) and smaller (pH)
than that of TLL and TS horses. Respiratory rate was sig-
nificantly reduced from awake values following anesthetic
induction (Table 2).
Average plasma glucose concentration of horses in all
three study treatments increased from baseline over the
course of anesthesia and reached their highest measured
levels of the study at the last sampling point, i.e., T75
(Table 3). Anesthetic induction and maintenance was
also associated with an increase in plasma lactate, and
small decreases in TPP concentration and temperature
(Table 3). Magnitude of initial change and time-related
values for each of these four variables was similar for the
three study treatments.
All recoveries were rated excellent. Time to standing
was significantly different between THL (60 ± 20 mi-
nutes) horses and those of both TLL and TS (32 ± 17
and 30 ± 15 minutes, respectively). All horses urinated
various unmeasured amounts during the anesthetic re-
covery period both while laterally recumbent, and again
within a short time after standing.
Discussion
The proposed hypothesis that lidocaine infusion would
increase antinociception and depth of xylazine/ketamine
anesthesia, without affecting cardiorespiratory variables,
was confirmed, and justifies the prolongation of anesthetic
recovery following the higher bolus dose and infusion rate
of lidocaine.
Results of the presently reported study confirm those
of previous reports of the IV anesthetic protocol used
[9,26], as well as the effects of a 50 μg/kg/min IV infu-
sion of lidocaine during general anesthesia in healthy
horses studied both under laboratory [27,28] and clinical
[18] conditions. In addition, presently reported results
extend current knowledge by offering insight to the use
of lidocaine during anesthesia maintained by injectable
drugs, as opposed to previous reports of inhalation
anesthesia [18,20,28,29], and highlights responses to two
different IV doses of lidocaine.Table 3 Mean (±SD) plasma glucose, lactate, total plasma pro
undergoing intravenous anesthesia with xylazine, guaifenesin
(THL), low dose of lidocaine (TLL) or saline infusion (TS)
Parameter Treat1
T0 T5
Glucose (mg/dL) Mean of treatments 103 ± 10 139 ± 22*
Lactate (mmol/L) Mean of treatments 0.80 ± 0.25 1.37 ± 0.39* 1
TPP (g/dL) Mean of treatments 7.2 ± 0.6 6.9 ± 0.5*
T°C (°C) Mean of treatments 37.9 ± 0.4 37.9 ± 0.4
1- Treat = Treatment; * - statistical difference from the time 0 or baseline value (row
of anaesthesia with xylazine, guaifenesin and ketamine respectively (and maintenan
lidocaine or saline infusion (data from the three groups were grouped).Presently reported circulatory and respiratory system
observations recorded over the course of anesthesia time
in the absence of lidocaine (i.e., TS horses) are quantita-
tively similar to those similarly gathered and reported by
Mama et al. [9,26] (Table 2). Mama et al. [9] postulated
that anesthetic maintenance with the similarly used IV
drug regime was at least slightly below the ED50 for move/
no move responses to a noxious electrical stimulus. The
noxious stimulus referred to was the same as that used in
the presently reported study, and the one commonly used
in determining the minimal alveolar concentration (MAC)
for inhalation anesthetics in horses [30]. The 20 moves
versus only 4 no move responses in response to the 24
stimulations in the present study (Table 1) are similar (ac-
tually a bit less than the earlier study) and these presently
reported data are in strong support of the hypothesis
voiced earlier by Mama and colleagues.
Bispectral electroencephalographic signal processing
has been investigated with human patients in an effort
to develop the EEG as a measure of anesthetic depth. In
humans, BIS is generally considered to be a good indi-
cation of CNS depression. The accuracy of the BIS
monitor in quantitating anesthetic depth specifically in
the horse has not been rigorously evaluated and
reported studies with this focus are very limited [31,32],
therefore the results should be considered with caution
due to the lack of validity of this technique in these
species. However, because of its considerable use with
human patients, its empirical trial with species of clin-
ical importance to veterinary medicine, like the horse is
logical. The presently reported study provided oppor-
tunity to compliment previous reports by gathering
additional empirical data on the utility of BIS recordings
under controlled conditions in anesthetized horses.
Values of BIS in our horses anesthetized without lido-
caine infusion were only minimally decreased (Table 1)
even immediately following anesthetic induction and
were close to the human awake, alert level of 100 (most
recordings were 95 or greater). These data support our
earlier comments regarding our horses being at a light
level of anesthetic recumbency.tein concentration (TPP) and temperature (T°C) in mares
and ketamine, combined with a high dose of lidocaine
Time (minutes)
T15 T30 T45 T60 T75
178 ± 39* 213 ± 42* 240 ± 44* 255 ± 50* 266 ± 55*
.51 ± 0.39* 1.62 ± 0.40* 1.70 ± 0.41* 1.73 ± 0.45* 1.76 ± 0.50*
6.8 ± 0.5* 6.7 ± 0.6* 6.7 ± 0.5* 6.7 ± 0.5* 6.8 ± 0.6*
37.9 ± 0.4 37.5 ± 0.4 37.3 ± 0.4* 37.2 ± 0.5* 37.0 ± 0.5*
) (P < 0.05). For all means n = 18; T5 and T15–5 and 15 minutes after induction
ce with xylazine and ketamine); T30, T60, T75–15, 45 and 60 minutes after
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THL), decreased in dose-related fashion both the BIS
and the number of moves (versus no move) in response
to noxious stimulation (Table 1) indicating an anesthetic
modifying effect of lidocaine (i.e., increased anesthetic
depth). BIS values were most reduced with the 100 μg/kg/
min rate of lidocaine infusion but there was large variation
in BIS values between individual horses. While providing
some qualitative measure of support of BIS application to
anesthetic management of an individual horse, especially
the large between-horse variability raises doubt about its
quantitative accuracy in a population of horses. These data
thus support previous investigators who questioned the
precision of BIS as an indicator of drug-induced CNS
depression and therefore minimized the clinical value, of
at least present development and understanding, of this
technology for anesthetic management of the horse
[31,32]. Much more evaluative information (pro or con) is
necessary to guide our understanding and conclusions of
BIS technology for equine applications.
Using a similar dose in sevoflurane anesthetized horses,
like TLL in this study, Rezende and co-workers [20]
reported a MAC reduction of 26.7 ± 12%, a value similar
to previous reports of lidocaine reduction of halothane
[17] and isoflurane [18] anesthetic requirement in ponies
and horses respectively. In Rezende et al. study mean
plasma lidocaine concentration ranged from a high of
2.6 ng/mL at the end of lidocaine bolus to 2.2 ng/mL at
the end of infusion. Except for the initial measurement,
these values are similar to those measured in the present
study at the 50 μg/kg/min rate (Table 1). The higher initial
plasma lidocaine values of the current study likely relate
to the higher loading bolus lidocaine injection and the
more rapid speed of injection used compared to the
sevoflurane MAC study (i.e., 2.5 versus 1.3 mg/kg, respect-
ively, and the 1.3 mg/kg dose administered over 15 mi-
nutes). Mean plasma lidocaine concentrations from T30
to the end of infusion were similar to those reported by
Rezende and coworkers using a similar IV lidocaine infu-
sion protocol during sevoflurane anesthesia of horses [20].
It is well established that lidocaine may produce con-
vulsions at high intravenous dosage in many species.
The lidocaine doses used in this study were below the
convulsant dose reported for cats [33], dogs [34,35], rats
[36], and monkeys [34]. However, doses were similar to
those that caused signs of toxicity in rabbits [33] and
humans [34]. The muscle tremors and sometimes force-
ful limb movements observed in our THL and some
TLL horses at the beginning of anesthesia were associ-
ated with high plasma lidocaine concentrations likely
due to the bolus administration over the short 5 minute
time period [33,34,37]. Meyer and colleagues [38]
reported skeletal muscle tremors in horses at plasma
lidocaine concentrations above 3.24 ± 0.74 μg/mL and,in the present study, the plasma lidocaine concentration
obtained at the end of the loading dose (T20) was signifi-
cantly greater than that. The pro-convulsive nature of
ketamine and the hypercapnea present at the time may
have further facilitated lidocaine-induced muscle tremors
and other limb movements we observed [1,33,34,39].
Doherty & Frazier [17] reported similar plasma lidocaine
concentrations in horses anesthetized with halothane.
However, muscle tremors were not reported associated
with their study. The apparent discrepancy between re-
sults of their study and our own may be explained on the
basis of a deeper level of anesthesia in the halothane anes-
thetized horses and associated masking or prevention of
the muscle activities. An alternative or additional explan-
ation may be the IV lidocaine loading dose was adminis-
tered over a longer period of time in the study of Doherty
& Frazier [17] (i.e., 15 minutes versus 5 minutes in the
presently reported study) and resulted in a lower peak
lidocaine plasma concentration.
In agreement with previously reported studies [18,28,29],
the addition of lidocaine had little consistent effect on
hemodynamic parameters (Table 2). Heart rate decreased
from baseline (pre-anesthesia) for all treatment and is pre-
sumed reflective of the direct and indirect effects of the
xylazine. Other than a tendency of systolic, and early in
the course of anesthesia, diastolic and mean arterial blood
pressures to be less during lidocaine infusion, there were
no dramatic differences between circumstances associated
with the presence or absence of lidocaine administration.
Time-matched arterial blood gas and acid base values
were similar regardless whether anesthesia was maintained
with or without lidocaine (Table 2). PaO2 and PaCO2 pre-
dictably increased in magnitude to acceptable ranges fol-
lowing anesthetic induction and supplemental inspired
O2. Not surprisingly lidocaine infusion had little effect on
PaO2 whereas, a modestly increased PaCO2 was associated
with lidocaine at the high infusion rate (THL), compared
to TLL and TS respectively.
Lactate increased over the course of anesthetic time
after all treatments similarly to previous studies [8,40-42],
implying that lidocaine administration had no important
influence on these temporal changes. Anesthetic-induced
increase in lactate concentration is commonly considered an
indication of anaerobic metabolism or depressed lactate me-
tabolism, as for example, accompanying general anesthesia.
Perhaps our most dramatic finding of this study was the
continued temporal increase in blood glucose following
preanesthetic medication with xylazine and anesthetic in-
duction, regardless whether or not lidocaine was adminis-
tered (Table 3). Lidocaine appeared to have no further
effect on the magnitude of hyperglycemia. Peak average,
maximal values of glucose concentration increased from
baseline of 254 and 267%, in TLL and THL respectively at
the end of anesthesia. Presumably the increase in plasma
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alpha-2 adrenergic agonist drug, xylazine. Alpha-2 ago-
nists diminish insulin release from the pancreas and thus
promote hyperglycemia, an action of routine prominence
in the horse [43,44]. While the initial rise in glucose was
expected, we were somewhat initially surprised by the
continued increase in glucose concentration over the
course of anesthetic time and drug cocktail administration.
To the best of our knowledge the present report is the first
such report of temporal increase in glucose concentration
accompanying constant infusion of xylazine (in this case
75 minutes). General anesthesia per se is likely not respon-
sible for the progressive plasma glucose increase especially
considering the magnitude of rise [45,46]. We presume
the progressive rise in glucose is related to the continuous
delivery of, in this case, xylazine over the more than 75
minute course of anesthesia. A similar temporal increase
in glucose was previously noted during continuous infu-
sion of detomidine-ketamine-guaifenesin to acepromazine
premedicated ponies [4].
The biological significance of the prolonged state of
hyperglycemia following prolonged alpha-2 agonist infu-
sion in horses remains unknown. Therefore we submit
that further investigation of prolonged alpha-2 agonist
administration and associated hyperglycemia, especially
to identify (or not) any medically adverse effects, is
warranted.
The low dose of lidocaine had no effect on post
anesthetic recover time compared to anesthesia in the ab-
sence of lidocaine infusion, while the high dose increased
recovery time. Such behavior is compatible with our earl-
ier described increased anesthetic action noted in THL
horses, both presumably related to central sedative effects
of lidocaine [17,18,20]. In this study, peri-anesthetic use of
lidocaine seemingly contributed neither positively or nega-
tively to the quality of recovery from general anesthesia
and the quality of anesthetic recovery in TS horses was
similar to that reported by Mama et al. [26].
Conclusions
Lidocaine infusion during xylazine/ketamine anesthesia
produced minor cardiorespiratory depression, and a dose-
dependent reduction in BIS and increase in antinociception.
Recovery was prolonged only with the higher bolus dose
and infusion rate of lidocaine.
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